What is the catalog number for LCS-1?

The catalog number for LCS-1 is HY-115445.

What sizes are available for LCS-1?

LCS-1 is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does LCS-1 come in?

LCS-1 is available in 6 different pack sizes.

LCS-1 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures LCS-1?

LCS-1 is manufactured by QuantiMol.

What is the estimated delivery time for LCS-1?

Estimated delivery time for LCS-1 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for LCS-1?

The safety data sheet for LCS-1 is available here: http://file.medchemexpress.com/batch_PDF/HY-115445/LCS-1-SDS-MedChemExpress.pdf.

LCS-1

LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC50 value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells[1][2][3].

Product Specifications

CAS Number

41931-13-9

Product Name Alternative

MK-0364 (racemate),R816

UNSPSC

12352005

Hazard Statement

H301, H319

Target

Apoptosis; SOD

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lcs-1.html

Concentration

10mM

Purity

99.81

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1C(Cl)=C(Cl)C=NN1C2=CC=CC(C)=C2

Molecular Formula

C11H8Cl2N2O

Molecular Weight

255.10

Precautions

H301, H319

References & Citations

[1]Gupta A, et al. Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells. Biomacromolecules. 2018 Mar 12;19 (3) :803-815.|[2]Somwar R, et al. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A. 2011;108 (39) :16375-16380.|[3]Du T, et al. Proteomic analysis identifies mechanism (s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia. 2021 Feb;35 (2) :550-561.